Modified gp41 Polypeptides for Soluble HIV Vaccine Trimers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing gp41 proteins for HIV vaccines face challenges such as insolubility in aqueous media, immunodominant cross-reactions with human proteins, and limited ability to induce neutralizing antibodies, necessitating the development of a stable and immunogenic form that can elicit a broad immune response across different HIV clades.
Innovation Solution
The creation of modified gp41 polypeptides in a trimeric, soluble form with reduced hydrophobicity, specifically designed to maintain native antigenicity and minimize IL-2 cross-reactivity, which are conjugated to virosomes for enhanced immunogenicity and stability, allowing for the induction of systemic and mucosal immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gp41 proteins are produced for HIV vaccines, then immune response induction is achieved, but insolubility in aqueous media occurs
Solution Approach 1:
The patent modifies the gp41 protein sequence by deleting specific hydrophobic amino acid residues (including residues 593-617 and other hydrophobic residues in the loop region) to change the protein's physical-chemical parameters. This reduces hydrophobicity and increases solubility in aqueous media while preserving the protein's ability to induce immune responses.
Solution Approach 2:
The patent extracts and removes specific hydrophobic regions from the gp41 protein structure, particularly the loop region between the N- and C-helices. By taking out these hydrophobic segments, the protein gains improved solubility while maintaining its functional epitopes for immune response induction.
2Ease of manufacture
If gp41 derivatives are modified to reduce hydrophobicity, then solubility is improved, but immunogenicity may be compromised
Solution Approach 1:
The patent applies local quality modification by selectively altering only the hydrophobic loop region while preserving the helical structures and epitopic regions. The N- and C-helices maintain their original sequences and immunogenic properties, while only the loop region is modified for solubility enhancement.
Solution Approach 2:
The patent changes the physical-chemical parameters of the gp41 protein by modifying amino acid sequences in specific regions. The overall protein structure and epitopic regions are preserved, while hydrophobicity parameters are adjusted in the loop region to achieve solubility without compromising immunogenicity.
3Reliability
If gp41 is used to induce immune response, then neutralizing antibodies are elicited, but cross-reactions with human proteins (IL-2) occur
Solution Approach 1:
The patent extracts and removes the specific epitopic region responsible for IL-2 cross-reactivity (residues 593-617) from the gp41 protein. By taking out this specific sequence, the protein maintains its ability to induce neutralizing antibodies against HIV while eliminating the harmful cross-reaction with human IL-2.
Solution Approach 2:
The patent segments the gp41 protein into distinct functional regions: the N-helix, C-helix, and loop region. By selectively modifying the loop region while preserving the helical structures, the protein maintains its immunogenicity for HIV neutralizing antibodies while removing cross-reactive epitopes.
4Reliability
If gp41 trimers are formed, then immune response is enhanced, but stability in aqueous media is reduced
Solution Approach 1:
The patent modifies the physical-chemical parameters of the gp41 trimer by altering the hydrophobicity of the loop region. This parameter change enhances the stability of the trimeric structure in aqueous media by reducing hydrophobic aggregation, while maintaining the trimeric conformation necessary for enhanced immune response.
Data Source
AI summary
The present invention deals with a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41 (N), a C-helix region of gp41 (C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2 (IL2).